AVITA Medical's book value per share for the quarter that ended in Mar. 2025 was $-0.17.
During the past 12 months, AVITA Medical's average Book Value Per Share Growth Rate was -113.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -66.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 28.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of AVITA Medical was 212.10% per year. The lowest was -66.70% per year. And the median was -20.90% per year.
AVITA Medical's current price is $5.17. Its book value per share for the quarter that ended in Mar. 2025 was $-0.17. Hence, today's PB Ratio of AVITA Medical is .
During the past 13 years, the highest P/B Ratio of AVITA Medical was 264.63. The lowest was 1.17. And the median was 5.59.
AVITA Medical Book Value per Share Historical Data
The historical data trend for AVITA Medical's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AVITA Medical's Book Value per Share
For the Medical Devices subindustry, AVITA Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical's PB Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where AVITA Medical's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
AVITA Medical (NAS:RCEL) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
AVITA Medical Book Value per Share Related Terms
Thank you for viewing the detailed overview of AVITA Medical's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCEL has been successfully added to your 